Les antagonistes de la cholécystokinine: Futurs antalgiques?

Douleur et Analgesie

Volumn 10, Issue 4, 1997, Pages 127-130

  Mann, C ^a  

^a HÔPITAL SAINT ELOI   (France)

Author keywords

CCK; CCK B antagonists; Endogenous opioids; Nociception

Indexed keywords

ANALGESIC AGENT; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; MORPHINE; OPIATE;

ANTINOCICEPTION; HUMAN; INTRACTABLE PAIN; MORPHINE TOLERANCE; POSTOPERATIVE PAIN; REGULATORY MECHANISM; SHORT SURVEY;

EID: 0031424164     PISSN: 1011288X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03003146     Document Type: Article

References (22)

1. Baber N.S.: 'The role of CCK, caerulein, and CCK antagonist in nociception. Pain 39, 307-328, 1989.
2. Durieux C.: Cholécystokinines et Gastrine In Neuropeptides et Neuromédiateurs. Coordinateur J Epelbaum, Sandoz Ed., Paris, 1992.
3. Docray G J.: Immunochemical evidence of CCK-like peptides in brain. Nature 264, 568-570, 1976.
4. B receptors in human brain: no evidence for receptor heterogeneity. Neuroscience Letter 217, 45-48, 1996.
5. Lignon M.F.: CCK increases intracellular calcium concentration in the human Jurkat T Lymphocyte cell line. Eur. J. Pharmacol. 245, 241-246, 1993.
6. Wang J.F.: Mobilization of calcium from intracellular stores as one of the mechanisms underlying the antiopioid effect of CCK-8. Peptides 13, 947-951, 1992.
7. Yamamoto T.: The effects of intrathecally administered FK480, a cholecystokinin-A receptor antagonist, and YM022, a cholecystokinin-B receptor antagonist, on the formalin test in the rat. Anesth. Analg 83, 107-113, 1996.
8. B receptor antagonist, L365,260 enhances morphine analgesia and prevents morphine tolerance in the rat Eur. J. Pharmacol 234, 147-154, 1993.
9. Noble F.: Modulation of opioid antinoception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br. J. Pharmacol. 109, 1064-1070, 1993.
10. Faris PL.: Evidence for the neuropeptide CCK as an antagonist of opiate analgesia. Science 219, 1449-1451, 1983.
11. Stanfa L.: CCK as a factor in the enhanced potency of spinal morphine following carageenan inflammatzion. Br. J. Pharmacol 108, 967-973, 1993.
12. Stanfa L.: CCK and morphine analgesia: variation on a theme. Trends Pharmacol. Sci. 88, 65-66, 1994.
13. Xu T.: CCK-8 reverses the kappa-opioid-receptor-mediated depression of calcium current in rat dorsal root ganglion neurons. Brain Res. 730, 207-211, 1996.
14. Noble F.: Role of endogenous CCK in the facilitation of mu-mediated antinociception by delta opioid agonists. J. Pharmacol. Exp. Ther. 271, 1127-1134, 1994.
15. Benoliel J.J.: Mu and delta receptors mediate opposite modulations by morphine of the spinal release of CCK-like material. Brain Res. 653, 81-91, 1994.
16. B agonist on asparate and glutamate release from rat hippocampal slices. Neuropharmacol. 33, 737-743, 1994.
17. Pu S F : Cholecystokinine octapeptide antagonizes morphine analgesia in nucleus accumbens of the rat via the CCK-B receptor Brain Res. 657, 159-164, 1994.
18. Zhou Y.: Accelerated expression of CCK gene in the brain of rats rendered tolerant to morphine Neuroreport 3, 1121-1123, 1992.
19. B antagonist C1988 enhances the reflex-depressive effect of morphine in axotomized rats. Neuroreport 5, 718-720, 1994.
20. Pu S.F.: CCK gene expression in rat amygdaloid neurons, normal distribution and effect of morphine tolerance. Brain Res Mol. 21, 183-189, 1994.
21. Benedetti F.: The opposite effects of the opiate antagonist naloxone and the CCK antagonist proglumide on placebo analgesia. Pain 64, 535-543, 1996
22. Lavigne G.: Proglumide potentiates morphine analgesia for acute postchirurgical pain. Clin. Pharmacol. Ther 45, 666-673, 1989.